INFORMATIONAL PURPOSES ONLY. Not medical, legal, or travel advice. Verify with official sources before acting. See corrections log.
Right to try laws and requirements in New Hampshire. Citations, verification dates, and source links for every data point.
| Dimension | Value | Citation | Source | Verified | Confidence |
|---|---|---|---|---|---|
| Have Enacted State Right to Try Laws | have state RTT laws | N.H. Rev. Stat. Ann. § 126-Z:2, I“A manufacturer of an investigational drug, biologic, or device may make available an investigational drug, biologic, or device to eligible patients pursuant to this chapter.” | Link | 2026-10-09 | high |
| Enacted Right to Try Laws Before Federal Law | 2016 | 2016 N.H. Laws ch. 206:2“Source. 2016, 206:2, eff. June 6, 2016.”Note: Stored 2017 is wrong. Chapter 126-Z source notes show the act was 2016 chapter 206, effective June 6, 2016; later amended by 2024 ch. 124, 2025 ch. 304 (HB 701, 'John Lewicke and Michael Yakubovich Right to Try Act', eff. Jan. 1, 2026) and 2026 ch. 311 (contingent). | Link | 2026-10-09 | high |
| Require Individualized Manufacturer Approval for RTT | require individualized approval | N.H. Rev. Stat. Ann. § 126-Z:1, I-c; § 126-Z:3, III(e)“"Individualized investigational treatment" means drugs, biologics, or devices unique to and produced exclusively for use for an individual patient, based on their own genetic profile, including but not limited to individualized gene therapy antisense oligonucleotides (ASO)”Note: Individualized investigational treatment provisions are enacted in RSA 126-Z (definition I-c; immunity for individualized treatments administered at an eligible facility, 126-Z:3, III(e)); 'qualifying severe illness' (chronic and debilitating) also covered. Caveat: the version shown on gc.nh.gov is labeled 'effective upon certified approval of a legislative report ... pursuant to 2026, 311:21' and the currently-effective text is not displayed, so it is unclear whether these provisions came from 2024 ch. 124 or 2026 ch. 311 and whether they are yet in force; either way they were signed into law. NH is also in the reported list of enacting states. | Link | 2026-10-09 | high |
| Provide Manufacturer Liability Protection Under RTT | provide liability shield sources differ | N.H. Rev. Stat. Ann. § 126-Z:3, III“a manufacturer of a drug, biologic, or device, a pharmacist, a health care facility, a health care provider, or a person or entity involved in the care of a patient using a drug, biologic, or device is immune from suit”Note: Immunity clause (not merely 'no private cause of action'), conditioned on terminal/qualifying severe illness, no comparable FDA-approved options, informed consent, and no 'willful or reckless misconduct or other bad faith conduct'. Ambiguous only as to timing: the displayed text is the version 'effective upon certified approval of a legislative report ... pursuant to 2026, 311:21' (source: 2016, 206:2; 2024, 124:1; 2025, 304:3; 2026, 311:15 contingent); the currently effective version is not shown on gc.nh.gov. Best value true. RSA 126-Z:4, I also says nothing in the chapter creates a private cause of action except injunctive relief against regulators. | Link | 2026-10-09 | medium |
| Require Insurer Coverage of Investigational Treatments | do not require coverage | N.H. Rev. Stat. Ann. § 126-Z:2, II“This chapter shall not require a health care insurer or any state agency to provide coverage for the cost of any investigational drug, biologic, or device.” | Link | 2026-10-09 | high |
View full New Hampshire profile (all layers) · Report an error on this page